POINT试验事后分析:既往抗血小板治疗不影响双联抗血小板疗效
该研究为POINT试验的事后分析,纳入4881例小卒中或高危短暂性脑缺血发作(TIA)患者,按随机化前是否使用抗血小板药分组。结果显示,既往抗血小板治疗与90天缺血性卒中风险无关,且双联抗血小板治疗降低卒中风险的效果不受既往用药影响。
要点
- 既往抗血小板治疗不增加小卒中/TIA后90天缺血性卒中风险。
- 双联抗血小板治疗降低卒中风险,不受随机化前抗血小板使用影响。
- 既往抗血小板治疗与大出血风险无显著关联。
核心结论
- 在小卒中和高危TIA患者中,双联抗血小板治疗降低缺血性卒中风险,无论病前是否使用抗血小板药。
研究设计与样本
- POINT试验的事后分析,纳入4881例患者,按随机化前抗血小板使用分为两组,41%无预处理抗血小板。
主要发现
- 90天缺血性卒中发生率在抗血小板预处理组为6%,无预处理组为5%。
- 抗血小板预处理与大出血风险无关(风险比1.10,95%CI 0.55-2.21;P=0.794)。
- 双联抗血小板治疗对复发缺血性卒中风险的影响在预处理组(校正风险比0.69,95%CI 0.50-0.94)与无预处理组(校正风险比0.75,95%CI 0.50-1.12)间无差异,交互P=0.685。
临床怎么用
- 对于小卒中或高危TIA患者,即使病前已使用抗血小板药,仍可考虑启动双联抗血小板治疗以降低卒中风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Dual antiplatelet therapy has been shown to reduce the risk of recurrent stroke in patients with minor stroke or transient ischemic attack. However, whether the effect of dual antiplatelet therapy is modified by pretreatment antiplatelet status is unclear. METHODS: This is a post hoc analysis of the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke). Patients were divided into 2 groups based on pretreatment antiplatelet use. The primary outcome was ischemic stroke within 90 days of randomization. RESULTS: We included 4881 patients of whom 41% belonged to the no pretreatment antiplatelet. Ischemic stroke occurred in 6% and 5% in the antiplatelet pretreatment and no antiplatelet pretreatment, respectively. Antiplatelet pretreatment was not associated with the risk of ischemic stroke (adjusted hazard ratio, 1.05 [95% CI, 0.81-137]) or risk of major hemorrhage (hazard ratio, 1.10 [95% CI, 0.55-2.21]; P=0.794). The effect of dual antiplatelet therapy on recurrent ischemic stroke risk was not different in patients who were on antiplatelet before randomization (adjusted hazard ratio, 0.69 [95% CI, 0.50-0.94]) as opposed to those who were not (adjusted hazard ratio, 0.75 [95% CI, 0.50-1.12]), P for interaction = 0.685. CONCLUSIONS: In patients with minor stroke and high-risk transient ischemic attack, dual antiplatelet therapy reduces the risk of ischemic stroke regardless of premorbid antiplatelet use.
引用
- Anadani M, de Havenon A, Henninger N, et al. Antiplatelet Use and Ischemic Stroke Risk in Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the POINT Trial. Stroke. 2021. PMID: 34634925. doi:10.1161/STROKEAHA.121.035354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。